Return to News Releases
SPHERICS AND TAKEDA ENTER COLLABORATION TO USE
SPHERICS’ BIOADHESIVE TECHNOLOGIES
- Agreement Seeks to Improve Oral Performance of Takeda Compound Under Development -
Mansfield, MA, June 28, 2006 - Spherics, Inc., a leader in applying bioadhesive technologies to improve therapeutic profiles of drugs, announced today that it has entered into a collaboration with Takeda Pharmaceutical Company Limited, the major global pharmaceutical company. Within the collaboration Spherics will apply its proprietary bioadhesive technologies to improve the performance of an orally active Takeda compound that is in development. Terms of the agreement were not disclosed.
“We are very excited to be working on improving the attributes of this Takeda product,” said Ze’ev Shaked, PhD, President and CEO of Spherics. “Our strategy is to create value from our bioadhesive technologies by building a proprietary pipeline of central nervous system drugs. We will complement this strategy by entering into a few selective collaborations with major global pharmaceutical companies for new product development, life cycle management and product line extensions. The Takeda agreement confirms the potential of our oral bioadhesive delivery technologies to enhance the pharmacokinetic and pharmacodynamic properties of compounds under development within the pipelines of leading global pharmaceutical firms.”
Spherics has developed advanced oral systems based on the application of proprietary bioadhesive polymers to oral dosage forms. These broadly enabling technologies have potential to expand the therapeutic benefits of drugs that otherwise do not remain at the target absorptive site long enough to be effective or have issues of low bioavailability when administered systemically. The benefits of the company’s technologies include improving efficacy, reducing side effects, providing more consistent drug levels and enhancing compliance. Spherics has demonstrated preclinical and clinical proof of concept that its novel bioadhesive technologies can significantly enhance the profiles of marketed drugs from a wide spectrum of chemical classes.
About Spherics
Spherics is an emerging pharmaceutical company developing products with improved therapeutic profiles for the treatment of central nervous system (CNS) diseases. The company’s portfolio, which currently includes six products in development, is based on its proprietary bioadhesive oral delivery platforms. Spherics is also selectively leveraging its bioadhesive oral delivery platform through collaborations with pharmaceutical companies for advanced formulation solutions, lifecycle management and product line extension. For more information, visit www.spherics.com.
